DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on July 16, 2007; DOI: 10.1124/dmd.107.016089


0090-9556/07/3510-1853-1859$20.00
DMD 35:1853-1859, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.016089v1
35/10/1853    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dixit, V.
Right arrow Articles by Unadkat, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dixit, V.
Right arrow Articles by Unadkat, J. D.

Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions

Vaishali Dixit, Niresh Hariparsad, Fang Li, Pankaj Desai, Kenneth E. Thummel, and Jashvant D. Unadkat

Department of Pharmaceutics, University of Washington, Seattle, Washington (V.D., K.E.T., J.D.U.); and Department of Pharmacokinetics and Biopharmaceutics, University of Cincinnati Medical Center, Cincinnati, Ohio (N.H., F.L., P.D.)

Although many of the clinically significant drug interactions of the anti-human immunodeficiency virus (HIV) protease inhibitors (PIs) can be explained by their propensity to inactivate CYP3A enzymes, paradoxically these drugs cause (or lack) interactions with CYP3A substrates that cannot be explained by this mechanism (e.g., alprazolam). To better understand these paradoxical interactions (or lack thereof), we determined the cytochromes P450 and transporters induced by various concentrations (0-25 µM) of two PIs, ritonavir and nelfinavir, and rifampin (positive control) in primary human hepatocytes. At 10 µM, ritonavir and nelfinavir suppressed CYP3A4 activity but induced its transcripts and protein expression (19- and 12- and 12- and 6-fold, respectively; a >2-fold change over control was interpreted as induction). At 10 µM, rifampin induced CYP3A4 transcripts, CYP3A protein, and activity by 23-, 12-, and 13-fold, respectively. The induction by rifampin of CYP3A activity was significantly correlated with its induction of CYP3A4 transcripts (r = 0.96, p < 0.05) and CYP3A protein (r = 0.89, p < 0.05). All three drugs (10 µM) induced CYP2B6 activity by 2- to 4-fold, CYP2C8 and 2C9 activity by 2- to 4-fold and the transcripts of CYP2B6, 2C8, and 2C9 by >3-, 5-, and 3-fold, respectively. CYP2C19 and 1A2 activity and transcripts were modestly induced (2-fold), whereas, as expected, CYP2D6 was not induced by any of the drugs. Of the transporters studied, protease inhibitors moderately induced multidrug resistance 1 (ABCB1) and multidrug resistance-associated protein (ABCC1) transcripts but had no or minimal effect on the transcripts of breast cancer resistance protein (ABCG2), organic anion-transporting peptide (OATP) 1B1 (SLCO1B1), or OATP1B3 (SLCO1B3). On the basis of these data, we concluded that many of the paradoxical drug interactions (or lack thereof) with the PIs are metabolismrather than transporter-based and are due to induction of CYP2B6 and 2C enzymes.


Address correspondence to: Dr. Jashvant D. Unadkat, Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195. E-mail: jash{at}u.washington.edu




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
M. D Liedtke and R C. Rathbun
Warfarin-Antiretroviral Interactions
Ann. Pharmacother., February 1, 2009; 43(2): 322 - 328.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. M Foisy, E. M Yakiwchuk, and C. A Hughes
Induction Effects of Ritonavir: Implications for Drug Interactions
Ann. Pharmacother., July 1, 2008; 42(7): 1048 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Gupta, G. M. Mugundu, P. B. Desai, K. E. Thummel, and J. D. Unadkat
Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors
Drug Metab. Dispos., June 1, 2008; 36(6): 1172 - 1180.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. D. Kharasch, D. Mitchell, R. Coles, and R. Blanco
Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1663 - 1669.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.